Loading...
•
Dec 31, 2023
Taysha Gene Therapies Q4 2023 Earnings Report
Reported financial results for the full year ended December 31, 2023, and provided corporate and clinical updates.
Key Takeaways
Taysha Gene Therapies reported full-year 2023 financial results, with revenue of $15.5 million compared to $2.5 million in 2022. The company's net loss was $111.6 million, or $0.96 per share, compared to a net loss of $166.0 million, or $3.78 per share in 2022. As of December 31, 2023, Taysha had $143.9 million in cash and cash equivalents.
Data from the first adult patient in the REVEAL Phase 1/2 trial showed that TSHA-102 was well-tolerated with sustained improvement across key efficacy measures.
The Independent Data Monitoring Committee approved the Company's request to proceed to early advancement to cohort two in the REVEAL adolescent and adult trial.
Revenue for the full year ended December 31, 2023, was $15.5 million.
Taysha had $143.9 million in cash and cash equivalents as of December 31, 2023.